ImmuCell Q2 product sales rise 11.5% to $7.2M; domestic sales up 27.7% YoY

IMMUCELL CORP /DE/

Q2 2026 total product sales $7.2M vs $6.4M in Q2 2025, an 11.5% increase.
Domestic sales grew 27.7% to $6.2M; international sales fell 38.9% to $1.0M.
First-half 2026 product sales $17.5M, up 20.9% from $14.5M in H1 2025.
Tri-Shield sales up 8.3% to $4.9M; Dual-Force and other sales up 19.1% to $2.3M in Q2.
Results are preliminary and unaudited; full Q2 earnings call scheduled for Aug 14, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.